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While diet and sedentary lifestyle remain important factors in the development of 
obesity, recent findings have shown the possible involvement of environmental 
obesogens, chemicals that can disrupt homeostatic energy balance and increase 
adiposity.  Bisphenol A (BPA) is a compound used in the manufacturing of plastics as a 
hardening agent and is ubiquitous in the environment due to its widespread use.  BPA 
has been shown to be an endocrine disruptor through its ability to mimic estrogen, 
which is now known to play important roles in adipose tissue growth and metabolism. In 
fact, a small but compelling number of studies have shown that mice exposed to BPA in 
utero or postnatally are fatter as adults.   
We hypothesized that BPA exposure exerts effects on adipose tissue, promoting 
adipogenesis and inflammation, and altering energy homeostasis in a manner that 
promotes obesity.  We tested our hypothesis using both in vitro and in vivo models.  
First, we found that low concentrations of BPA increased the expression of the 
inflammatory genes, Il-6 and Tnfa, approximately 1.5-3.0 fold in mouse adipose tissue 
explants.  We also found a 3-fold increase in the expression of the lipogenic gene, 
Fasn.  BPA also altered the adipose tissue metabolism, increasing the levels of a 
number of glycolytic and TCA cycle metabolites, suggesting that BPA may disrupt 
energy homeostasis.  We also found that BPA exposure increased proliferation of 
mesenchymal stem cells approximately 1.2-fold, which are potential adipocyte 
precursors.  The study was expanded using two different strains of mice, C57BL/6 and 




moderate concentration of BPA increased the perigonadal fat pad mass in males.  This 
increase in adiposity was associated with adipocyte hypertrophy and decreased serum 
adiponectin levels.  There were also changes in the expression of some genes with 
BPA treatment, including a 1.4-fold increase in Leptin and decreases in some 
Cytochrome P450 genes; however the genes differentially expressed were different 
between the two strains.  Our results suggest that childhood exposure to low doses of 
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Obesity and the Role of Adipose Tissue 
The incidence of obesity has increased dramatically over the past 25 years.  
More than 300 million people, worldwide, are obese, and the majority of developed and 
rapidly developing countries have seen dramatic increases in obesity (James, 2004, 
James et al., 2001).  Obesity occurs when body fat becomes excessive and adversely 
affects other organs such as the heart and liver.  This obesity epidemic has garnered 
much attention in recent years due to the overwhelming burden that obesity and its 
comorbidities (diabetes, cardiovascular disease, cancer, etc.) have put on the 
healthcare system.  The estimated annual healthcare cost for obesity was 147 billion 
dollars in 2008, or up to 9.1% of annual healthcare cost compared to 6.5% in 1998 
(Finkelstein et al., 2009).  Recently, there was passage of a new healthcare bill in the 
United States.  During this debate, there was a fair amount of discussion about ways to 
cut cost.  Curbing the obesity trends in this country would certainly be one solution to 
reduce healthcare spending. 
Obesity occurs as a result of a disruption of the body’s energy homeostasis.  
When caloric intake far exceeds energy expenditure, excess energy is stored as fat in 
adipose tissue.  The disruption of the body’s energy balance equation has become 
inherently easier to incur as a result of the modern Western lifestyle.  The average 




sodium.  Many of the factory and industrial jobs that required physical labor have been 
replaced with office jobs, which have led many Americans to become much more 
sedentary.  The combination of diet and inactivity has created an obesogenic 
environment in the United States and other western countries, and there is evidence 
that similar trends are occurring in developing nations, such as China and India 
(Cecchini et al., 2010). 
Body fat, or adipose tissue, is the main repository for excess energy.  The 
primary function of adipose tissue is to store the body’s excess energy in the form of 
triglycerides.  Adipose tissue is primarily made up of fat cells, or adipocytes, but it also 
contains other cells types such as macrophages and fibroblasts.  Adipose tissue also 
contains preadipocytes that can undergo adipogenesis, or differentiate into mature 
adipocytes.  Adipogenesis is regulated by the transcription factors peroxisome 
proliferator activate receptor gamma (PPARγ) and CCAAT-enhancing-binding proteins 
(C/EBPs), which, once activated, increase transcription of genes that change cell 
morphology and signal the adipocyte to begin storing lipids (Rosen et al., 2000).There 
are many different depots of adipose tissue throughout the body, and they each have 
different metabolic profiles.  One of the most well known depots is the visceral fat that 
accumulates around the abdomen.  Excessive abdominal fat is the depot most 
commonly associated with obesity and its comorbidities.  Obesity can proceed through 
a combination of adipocyte hypertrophy, hyperplasia, or combination of both (de 
Ferranti and Mozaffarian, 2008).  As energy intake far outweighs energy expenditure, 




expand, they signal preadipocytes to proliferate and undergo adipogenesis, thus 
increasing the number of mature adipocytes (Avram et al., 2007) 
While the primary role of adipose tissue is the storage of excess energy, it is now 
known that adipose tissue acts as an endocrine organ (Siiteri, 1987, Zhang et al., 1994).  
Along with producing and secreting traditional hormones such as estrogen, adipose 
tissue produces and secretes a number of adipose-derive hormones.  These hormones 
include the appetite regulator, Leptin, and glucose regulator, Adiponectin, as well as the 
inflammatory cytokines, tumor necrosis factor, alpha (TNFα) and interleukin-6 (IL-6).  A 
chronic state of inflammation is associated with excess body fat, which may be a 
contributing factor to the diseases associated with obesity such as insulin resistance 
and cardiovascular disease (Shoelson et al., 2007).  Furthermore, the inflammatory 
cytokines released from adipose tissue may promote adipocyte proliferation and 
expansion, creating a vicious cycle where adipose tissue expansion promotes 
inflammation, which, in turn, promotes adipose expansion (Avram et al., 2007). 
Environmental Obesogens 
 The main driving force promoting obesity is disruption of the body’s energy 
homeostasis, i.e. caloric intake far outweighing energy expenditure.  Many believe that 
humans evolved to be able to sustain long periods of time with little food, and the 
modern Western lifestyle (high calorie diet, sedentary lifestyle) has led to the increased 
prevalence of obesity (Hales and Barker, 2001).  While this theory certainly makes 




thirty years.  Human exposure to synthetic chemicals has also increased dramatically 
over the past half century, concurrently with the increase in obesity (Baillie-Hamilton, 
2002).  A number of these chemicals are produced during many manufacturing and 
agricultural processes.  Some are commonly used in many household items making it 
difficult to limit human exposure.  The “environmental obesogen” hypothesis proposes 
that a number of environmental chemicals can disrupt homeostatic energy balance, lipid 
metabolism, and adipogenesis, leading to increasing adiposity (Grun and Blumberg, 
2007, Grun and Blumberg, 2009a).  The term “obesogen” was first used by Dr. Bruce 
Blumberg of the University of California Irvine in 2006, and a Pubmed search of 
“obesogen” produces only nine hits, so the idea that synthetic chemicals in the 
environment can promote obesity is a fairly novel one.   
 While the term “environmental obesogen” is a new one, the number of chemicals 
with possible obesogenic properties is not low.  A number of these chemicals are 
environmental pollutants, such as phthalates, organotins, bisphenol A (BPA), and 
perfluoroalkyl compounds (PFCs) (Grun and Blumberg, 2009a).  Other sources of 
possible environmental obesogens include nutritional components, such as 
phytoestrogens, and pharmaceutical components, such as diethylstilbestrol (DES) and 
thiazolidinediones (TZDs) (Newbold et al., 2007, Heindel and vom Saal, 2009). 
Perhaps the most compelling evidence for environmental factors contributing to 
obesity is the increase in the number of overweight infants; the prevalence of 
overweight infants under 6 months old has increased 73% since 1980 (Kim et al., 2006).  




months, overweight was defined as weight-for-length greater than the 95th percentile.  
While there are a number of possible explanations for increased adiposity in newborns 
(maternal diet, epigenetics, etc.), in utero exposure to environmental pollutants is one 
certainly of great concern.  Mothers can control their diets, but many of these chemicals 
are ubiquitous in the environment making it difficult to limit human exposure 
(Vandenberg et al., 2007).  The concept of environmental obesogens is closely linked 
with Barker’s hypothesis, or “the fetal basis of adult disease” theory.  David Barker 
proposed this hypothesis in the 1980’s to explain the correlation between low birth 
weight and a number of chronic conditions later in life, including cardiovascular disease 
and diabetes (Barker et al., 1989).  Barker hypothesized that poor nutritional conditions 
in utero lead the fetus to adapt to an environment limited in nutrients.  The fetus is 
essentially programmed for survival in a limited nutrient environment, but is born into an 
environment where nutrients are far from limited.  The fetal basis for adult disease 
paradigm has been validated for obesity by a number of other in utero and perinatal 
conditions, such as maternal smoking, that result in increased adiposity later in life.  The 
effect that in utero exposure to these chemicals may have on development is widely 
unknown, but a number of these chemicals are endocrine disruptors, compounds that 
can mimic and disrupt the body's natural hormones, specifically estrogen (Grun and 
Blumberg, 2009b).   
Endocrine Disruptors 
Endocrine disruptors are exogenous chemicals that mimic and disrupt the 




believed to adversely affect gene expression and development of a number of systems 
(Colborn et al., 1993).  Furthermore, exposure to these chemicals at other critical times 
in one’s lifespan could have detrimental effects on systems that require hormonal signal 
to function properly (i.e. sexual development, reproduction, etc.).  Reproductive 
problems, early puberty, behavioral problems, and even some cancers are some of the 
health problems that have been attributed to endocrine disruptors (Birnbaum and 
Fenton, 2003, Safe, 2004).  These chemicals not only mimic the hormones of humans, 
but they can also have the same adverse effects on wildlife that are exposed, raising 
concerns about the impact that endocrine disruptors in the environment may have on a 
variety of organisms (Kloas, 2002). 
An endogenous hormone binds its specific or group of specific hormone 
receptors to mediate its signaling and action.  Endocrine disruptors, which generally 
share some structural similarity with the endogenous hormone, can also interact with 
the hormone receptor leading to disruption of the process.  An endocrine disruptor may 
not be biologically active leading to attenuation of the signaling, or it may be more 
biologically active than the endogenous hormone leading to increased signaling.  
Endogenous hormones are also regulated by the body in a number of ways, including 
feedback inhibition, none of which would have an effect on exogenous endocrine 
disruptors (Zoeller, 2005, Ghisari and Bonefeld-Jorgensen, 2005). 
The effect that endocrine disruptors have on the function of sex steroids, such as 
estrogen and androgen, is of particular concern.  Dysfunction in the secretion or action 




alike (Safe, 2004, Kloas, 2002).  While the primary function of adipose tissue is to store 
energy in the form of fat, it is now known that adipose tissue also acts as an endocrine 
organ, synthesizing and secreting its own set of hormones known as 
adipokines(Kershaw and Flier, 2004).  Adipocytes also express and secrete sex 
hormones, such as estrogen, and their receptors, and these hormones regulate adipose 
tissue development (Siiteri, 1987).  Therefore, endocrine disrupting chemicals could 
potential disrupt adipocyte metabolism and energy homeostasis.  Knockout models for 
certain components of the sex steroid pathway (aromatase, estrogen receptor, etc.) can 
result in dysregulation of adipocyte size and number and affect the sexually dimorphic 
deposition of adipose tissue (Heine et al., 2000, Murata et al., 2002).  Loss of estrogen 
in mice via ovariectatomy results in weight gain and obesity, and menopausal women 
tend to gain body fat (Demir et al., 2008). Taken together, these data suggest that sex 
hormone dysregulation can have pro-adipogenic effects. 
There are also a number of nuclear hormone receptors that act as regulators of a 
number of pathways important to adipose tissue, such as lipid metabolism and 
adipocyte proliferation and differentiation.  Peroxisome proliferator activated receptors 
(PPARs) are the most important of these receptors, particularly the gamma isoform 
(PPARγ).  Activated PPARγ increases the expression of key adipogenic genes that 
promote the storage of fatty acids and decreases the expression of lipolysis genes 
(Ferre, 2004).  PPARs form heterodimers with 9-cis retinoic acid receptor (RXR) that 
can function as metabolic sensors for a variety of lipophilic hormones.  The formation of 




is dependent on the activation of RXR-PPARγ (Rosen et al., 1999).  The anti-diabetic 
drugs rosiglitazone and pioglitazone are PPARγ agonists that improve insulin sensitivity 
but result in increased weight gain (Larsen et al., 2003).  The fact that a pharmaceutical 
agent can act as an obesogen through the activation of PPARγ would suggest the 
possible existence of other chemicals with similar effects.  Recent findings have shown 
that some organic pollutants that are endocrine disrupting chemicals can also activate 
both the RXRs and PPARγ (Grun et al., 2006).  
Bisphenol A 
Bisphenol A (BPA) is an organic compound containing two equivalent phenol 
groups that was first synthesized in 1891 (Figure 1-1).  In the 1930’s, it was discovered 
that BPA has estrogenic properties, however its use as a synthetic estrogen was 
abandoned in favor of diethylstilbestrol (DES), which was determined to have more 
potent effects.  DES was prescribed to women to help with difficult pregnancies, but it 
was discovered after it had been given to millions of women, over 30 years later, that 
DES was a carcinogen and could lead to reproductive defects in girls born to mothers 
taking DES.  If DES could have such an adverse effect, it stands to reason that a 
chemical with similar chemical structure and properties such as BPA could have similar 
toxic effects. 
In the 1940’s, BPA began to be used in the production of plastics.  BPA is used 
as a hardening agent in consumer plastics and is found in a number of different types, 






















 fillings, CDs/DVDs, and household electronics.  The epoxy resins that are used in 
canned food and beverage linings contain BPA, and it has commonly been used in the 
plastics that make baby bottles.  The widespread use of BPA has led it to be one of the 
most produced chemicals in the world, at 2 million tons a year (Lang et al., 2008).  The 
increased production and prevalent use has made BPA a ubiquitous chemical in 
theenvironment.  The population is directly and chronically exposed to BPA through 
consumption due to its use in food and beverage packaging and storage containers, 
with exposure increased due to the fact that BPA leaches from plastics when exposed 
to heat or acidic environments (Le et al., 2008, Vandenberg et al., 2007).   
Many of the effects that BPA has on health were first discovered by accident.  In 
1993, it was discovered that BPA leached from autoclaved polycarbonate flasks, 
leading to increased proliferation of breast cancer cells (Krishnan et al., 1993).  
Accidental exposure to BPA due to damaged polycarbonate cages led to disruption of 
meiosis in the oocyte of control female mice (Hunt et al., 2003).  A study from the vom 
Saal lab tested the effects of BPA on blood serum and found that BPA had a higher 
binding affinity in serum than estradiol, indicating greater estrogenic bioactivity (Nagel et 
al., 1997).  Furthermore, exposing pregnant mice to small amounts of BPA (2µg/kg/day) 
resulted in significantly larger prostates in male offspring compared to controls.  This 
dose was 25,000 times lower than the toxic threshold set by the EPA 
(http://www.epa.gov/IRIS/subst/0356.htm). 
The concern over BPA has grown over the last few years; however, there is still 




consistency in findings, and a number of studies contradict one another.  Perhaps some 
of the dispute can be traced to the chemical companies that have an interest in 
protecting their multi-billion dollar industry.  Over 90% of independently funded studies 
have found that BPA exposure at biologically relevant doses result in adverse health 
effects.  However, every industry-funded study has found that BPA has no effect on 
health (vom Saal and Myers, 2008).   
While chemical companies are trying to protect their own interest, there is 
legitimate debate and differences of opinion over data interpretation and the potential 
toxicity of BPA.  For decades, a traditional toxicological approach was taken to study the 
effects of BPA.  Extremely high doses of BPA were found to have adverse effects such 
as organ failure and cancer, but doses below a certain threshold were safe.  There is 
now evidence that low doses, well below the threshold, have a completely different set 
of effects, which can effect development and metabolism.  Proponents of BPA still 
dispute these findings, saying that the doses used in many of these studies (micromolar 
range) are still higher than environmentally relevant doses (low nanomolar range) (Ben-
Jonathan et al., 2009).  Another issue is the non-monotonic dose response of BPA.  
Most studies lack a linear dose-dependent curve of BPA effects, making it difficult to 
extrapolate the action of BPA.  While the debate remains open, it is clear that BPA can 






Bisphenol A and Obesity 
 BPA’s endocrine disrupting properties, and its abundance in the environment has 
led it to be categorized as a potential environmental obesogen.  The potential for BPA to 
increase adiposity was also first discovered by accident in 2001.  The Rubin lab was 
studying the reproductive effects that BPA exposure had on pregnant rats.  There had 
been some studies on the effect of BPA exposure in adult rodents but very few had 
examined the effects of perinatal exposure, which could produce more detrimental and 
irreversible effects.  They found that the rats treated with a high dose (1.2 mg/kg body 
weight (bw)/day) or low dose (0.1 mg/kg bw/day) of BPA via drinking water produced 
heavier offspring compared to controls, and this phenotype persisted through adulthood 
(Rubin et al., 2001).  Interestingly, the offspring from the lower dose were slightly 
heavier than the offspring of the high dose, indicating that the lower doses may be more 
detrimental in regards to adiposity than higher doses.  They also found that female 
offspring exposed to the high dose had altered estrous cycles and decreased levels of 
plasma luteinizing hormone.   
There have been a limited number of studies that further explored these effects 
of BPA, and a number of them have used extremely high doses. Some in vitro studies 
have shown that BPA can promote adipogenesis, increase expression of adipogenic 
genes, and promote inflammation.  Hugo and colleagues studied the effects that low 
doses of BPA and E2 have on secretion of adiponectin from adipose explants and 
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adiponectin secretion from adipose tissue and mature adipocytes, alike (Hugo et al., 
2008).  They also found that BPA increased the secretion of the pro-inflammatory 
cytokines, tumor necrosis factor α (TNFα) and interleukin-6 (IL-6).  Sargis and 
colleagues tested the ability of a number of endocrine disrupting chemicals (EDCs) to 
stimulate the glucocorticoid receptor (GR) due to its central role adipocyte differentiation 
(Sargis et al., 2009).  They treated 3T3-L1 preadipocytes with a variety of EDCs and 
assessed the ability of each to activate GR using a luciferase reporter construct.  They 
found that BPA was one of four chemicals that stimulated activationof GR at a 
concentration of 1 µmol/L.  BPA also increased lipid accumulation in differentiating 
adipocytes and increased expression of adipogenic proteins. 
Howdeshell and colleagues fed pregnant mice BPA at a dose of 2.4µg/kg bw 
between days 11 and 17 of gestation.  The offspring had similar birth weights.  
However, after weaning, female mice treated with BPA were significantly heavier than 
female controls (~10.5g compared to 9.25g).  The results were very similar in the male 
counterparts (Howdeshell et al., 1999).  They also found that the female mice exposed 
to BPA began ovulation earlier.  To our knowledge, there has been only one study that 
has addressed BPA’s effect on fat tissue.  The Somm laboratory sought to determine 
the effect that perinatal exposure to BPA has on early adipose storage.  Pregnant rats 
were exposed to BPA through drinking water at a dose of 1mg/L at day 6 of gestation 
through the end of lactation.  The offspring were weaned and sacrificed at day 21 to 
study the perigonadal adipose tissue.  They found that the birth weight for both males 




increased in the females at the time of sacrifice.  They also found that gestational 
exposure to BPA increased parametrial white adipose tissue (WAT) in female rats 3-
fold.  The increased pWAT was attributed to adipocyte hypertrophy; females exposed to 
BPA had significantly larger adipocytes (Somm et al., 2009).  The exposed females also 
had increased expression of lipogenic genes, such as Pparg and fatty acid synthase 
(Fasn).  These studies indicate that BPA exposure, particularly early in life, may alter 
adipose energy homeostasis in a way that is promoting fat storage and obesity, 
however the effect of postnatal and early childhood exposure remains unknown. 
BPA is a lipophilic compound, therefore, it can accumulate in fat.  Obesity is 
associated with chronic low-level inflammation that can contribute to further 
complications, such as cardiovascular disease (Grundy, 2004, Xu et al., 2003).  BPA 
has been shown to upregulate important inflammatory cytokines and adipokines in 
adipose tissue explants, and a few in vitro studies have shown that it increases 
expression of pro-inflammatory cytokines, such as TNFα and IL-6 in macrophages 
(Yamashita et al., 2005, Yan et al., 2008, Hugo et al., 2008).  Mice exposed to low 
levels of BPA in utero exhibited increased production of T-cell activating cytokines and 
diminished numbers of regulatory T-cells as adults, favoring inflammation (Yan et al., 
2008).  In humans, there have been significant correlations shown between urinary BPA 
levels and markers for inflammation (Melzer et al., 2010), and in post- but not pre-
menopausal women, significant correlations have been shown between urinary BPA 
concentrations and markers of oxidative stress and inflammation (including C-reactive 




Both adipocytes and the stromal vascular fraction of cells in adipose tissue secrete pro-
inflammatory cytokines.  Studies now indicate that the inflammatory process of obesity 
begins before there are large changes in adipose tissue mass due to the infiltration of 
macrophages and CD8+ T-cells.  These cells disrupt adipocyte metabolism and insulin 
sensitivity by secreting cytokines and promoting local inflammation within the adipose 
tissue (Greenberg and Obin, 2006, Cinti et al., 2005).  If BPA increases adipose mass 
through adipocyte hypertrophy or hyperplasia, there would be an expected parallel 
increase in inflammatory adipokines.  This indirect effect along with the direct effect that 
BPA may have on expression of TNF-α and IL-6 could have great consequences, 
specifically the manifestation of the metabolic syndrome. 
Along with promoting inflammation, there is concern that developmental 
exposure to BPA may increase the number of adipocyte precursors and promote 
adipocyte differentiation.  3T3-L1 fibroblasts treated with BPA increased expression of 
important adipogenic genes, however, the doses used were well outside the biologically 
relevant range (Phrakonkham et al., 2008, Vandenberg et al., 2009).  If BPA increases 
preadipocyte proliferation, adipogenesis, and inflammation at doses similar to human 
exposure (low nanomolar range), it could be an important contributing factor to the 
metabolic syndrome and the current obesity epidemic (Figure 1-2). 
There have been a number of epidemiological studies to determine the level of 
exposure to BPA in humans and the possible adverse health effects of exposure.  
Perhaps the most widely known is the data acquired from the National Health and 

















Figure 1-2.  Model depicting various factors contributing to obesity and 
the metabolic syndrome. BPA decreases secretion of Adiponectin which 
results in decreases in insulin sensitivity.  BPA also increases secretion of 
inflammatory cytokines from adipocytes which promotes insulin resistance as 
well as atherosclerosis and hypertension, all of which are part the metabolic 




first large scale view of BPA levels in the US population.  Approximately 1500 adult 
participants, ages 18 to 74, with measured urinary BPA were assayed for chronic 
disease diagnosis as well as markers of liver function, glucose homeostasis, 
inflammation, and lipid changes.  BPA was detected in the urine of over 92% of 
participants.  This study found that higher urinary BPA levels were associated with 
increased incidence of coronary heart disease, even after regression models are 
adjusted for sex, age, smoking, BMI and other known variables that affect 
cardiovascular disease (Lang et al., 2008).  Higher BPA concentrations were also 
associated with diabetes, and individuals with BMI’s over 35 had nearly twice the level 
of BPA compared to individuals within the normal range (6.93 ng/mL compared to 
3.91ng/mL).  This study also suggested correlation between C-reactive protein levels 
and urinary BPA , although the relationship did not reach statistical significance when 
the model was fully adjusted for all potential covariates.  
In a more recent study, Melzer and colleagues (Melzer et al., 2010) conducted a 
similar cross-sectional analysis with data from the NHANES 2005/06 study as well as 
data pooled across both studies.  Despite average BPA levels being 30% lower in the 
2005/06 group compared to the 2003/04 group, they also found that higher urinary BPA 
levels were associated with coronary heart disease in the 2005/06 cohort, as well as the 
pooled data.  However, association with diabetes was not significant in the 2005/06 
data, but remained significant in the pooled data.  The decrease in average BPA levels 
is most likely due to increased consumer awareness and the decreased use of certain 




study to assess BPA exposure in the US general population included children of 6 years 
of age or greater (Calafat et al., 2008).  They found that children ages 6-11 had the 
highest levels of urinary BPA of any age group, indicating a disproportionate level of 
accumulation or exposure in children.  This is especially troubling considering children 
may be the group most susceptible to BPA’s potential toxic effects.     
Metabolic actions of BPA 
While it is unknown how BPA mediates its action on adipose tissue and other 
systems, there are a few of potential interactions that could explain BPA’s effect (Ben-
Jonathan et al., 2009).  The most well known interaction occurs between BPA and the 
classical estrogen receptors ERα and ERβ.  BPA has been shown to interact with these 
receptors (Gould et al., 1998, Kuiper et al., 1998), and it’s possible that BPA disrupts 
the endogenous estrogen signaling. However BPA binds these receptors much weaker 
than estradiol and should not be able to compete with endogenous estrogen at the low 
levels that humans are exposed, yet it does (Gould et al., 1998).  There are a number of 
speculations to explain the disparity.  It is thought that BPA may bind to the estrogen 
receptors differently than endogenous estradiol as a result of some interaction between 
BPA and serum proteins or some co-ligands.  These interactions allow BPA to bind the 
ERs near the same strength of estradiol and compete in the nanomolar range 
(Welshons et al., 2006, Safe et al., 2002). BPA may also elicit a rapid response by 
binding non-classical membrane estrogen receptors (ncmERs) (Alonso-Magdalena et 
al., 2005) or estrogen-related receptors (ERRs) (Ben-Jonathan et al., 2009, Takayanagi 




actions of E2 on blood glucose homeostasis through two different pathways: a rapid 
pathway via ncmER and a prolonged pathway via ER.  Overstimulation of these 
receptors by BPA on the β-cells increased insulin biosynthesis and secretion leading to 
insulin resistance.   
There have been few studies looking at the effects of BPA on adipose tissue in 
vivo; however many of these have conflicting data, most likely due to the wide range of 
doses used.  Some studies have found that BPA exposure increases adipose mass in 
rats (Somm et al., 2009), and others find that certain doses have no effect or actually 
decrease body weight (Nunez et al., 2001, Seidlova-Wuttke et al., 2005). This is a major 
issue with attributing BPA to a number of adverse effects.  As stated previously, Hugo et 
al. found that BPA at low nanomolar concentrations inhibited the release of adiponectin 
from isolated human adipocytes and stimulated the release of IL-6 and TNFα, a direct 
effect of BPA that would be predicted to diminish insulin sensitivity (Hugo et al., 2008).  
There is also evidence that BPA may activate the key adipogenic regulator PPARγ.  
BPA treatment significantly up-regulated PPARγ in a dose dependent manner in human 
granulose cells, resulting in reduced insulin-like growth factor 1 (IGF-1) and aromatase 
expression and E2 secretion (Kwintkiewicz et al., 2010). 
It is clear that BPA has endocrine disrupting properties and can have adverse 
effects on health, especially at extremely high doses.  The effects that BPA has at low 
doses are not quite as clear.  Along with studying the effects that nanomolar doses of 
BPA has on adipocyte endocrine function, gene expression, and overall adiposity, we 




if biologically relevant levels of Bisphenol A (BPA) effect the development, endocrine 






GENERAL EXPERIMENTAL DESIGN 
 Our goal is to determine if biologically relevant levels of Bisphenol A (BPA) effect 
the development, endocrine function, and metabolism of adipose tissue in a way that 
promotes obesity.  The ultimate purpose is to identify the potential metabolic pathways 
and genes that mediate response to BPA and ultimately understand the effects of BPA 
on adiposity.  The research employed both in vitro and in vivo methods to meet these 
goals. 
 We began by assessing the effects of BPA using in vitro systems.  Adipose 
tissue ex-plants were exposed to varying doses of BPA and analyzed for gene 
expression and changes in metabolism.  We also used mesenchymal stem cells 
(MSCs) to assess the effects that BPA has on proliferation and adipogenesis (Part 1). 
 Secondly, we used two strains of mice (C57BL/6J and DBA/2J) to look at the 
effects that biologically relevant levels of BPA has on overall adiposity and adipose 
tissue gene expression, endocrine function, and metabolism (Part 2).  BPA was 
delivered orally, via drinking water, which is the most common route of exposure in 
humans.  Mice were exposed to BPA from 4 weeks of age to 12 weeks of age.  
Intraperitoneal glucose tolerance tests (GTTs) were conducted at 8 weeks of age.  
Adipose tissue was collected and analyzed for changes in gene expression (Illumina®), 
metabolism (mass spectrometry), and protein levels (Luminex®).  We also collected 







 Figure 2-1.  Experimental design: in vitro experiments.  Adipose tissue explants 
from 16 BXD mice were exposed to various concentrations of BPA and estradiol for 24 
hrs.  Tissue was then snap frozen and pulverized for metabolic and gene expression 
analyses.  Mouse mesenchymal stem cells were treated with various concentrations of 
BPA and estradiol for 24 or 48 hours and proliferation rate was determined using the 





Figure 2-1.  Experimental design: in vivo experiment.  Mice were exposed to various 
doses of BPA and sacrificed after 8 weeks of treatment.  Adipose tissue was harvested 
an snap frozen or placed in RNAlater.  Tissue was used to analyze gene expression, 






EFFECTS OF BISPHENOL A ON ADIPOCYTE GENE EXPRESSION, 
METABOLISM, AND PROLIFERATION 
Introduction 
 Bisphenol A (BPA) is a chemical found in many items that humans use daily, 
including polycarbonate plastics.  BPA is structurally similar to the potent synthetic 
estrogen, diethylstilbestrol (DES), and it is clear that BPA has endocrine disrupting 
properties as well (Alonso-Magdalena et al., 2005, Krishnan et al., 1993).  Adipose 
tissue has a critical role as an endocrine organ, along with its role of energy storage.  It 
not only responds to traditional hormones, but it also produces and secretes its own set 
of peptides, adipokines, which play an important role in regulating physiology and 
inflammation (Kershaw and Flier, 2004).  Adipose tissue also produces and secretes 
sex hormones (Siiteri, 1987).  Therefore, a known endocrine disruptor such as BPA 
could have an adverse effect on the endocrine function and metabolism of adipocytes.  
We hypothesize that low doses of BPA, similar to levels exposed to humans, can 
disrupt normal gene expression and endocrine function in a way that would promote 
adipocyte expansion and inflammation. 
 Adipose tissue is primarily made up of adipocytes, but it also consists of a 
variety of other cell types including fibroblasts and macrophages (Balistreri et al., 2010, 




cytokine, TNFα, from adipose tissue (Ben-Jonathan et al., 2009).  If BPA increases 
adipose tissue mass, there were would a parallel increase in inflammation.  However, if 
BPA directly increases expression and secretion of pro-inflammatory adipokines, this 
could increase the number of infiltrating macrophages which would further exacerbate 
the inflammation and increase the risk of developing cardiovascular disease or type II 
diabetes (Hugo et al., 2008, Fantuzzi, 2005).  We measured the expression of two 
important inflammatory adipokines, TNFα and IL-6, in adipose tissue explants exposed 
to BPA. There is also a strong correlation between TNFα production, adiposity, and 
insulin resistance (Ryden and Arner, 2007).  .  If BPA directly increases production of 
inflammatory adipokines, this would support the idea that BPA and other endocrine 
disruptors can regulate inflammatory adipokines independent of adipocyte hypertrophy 
(Newbold et al., 2007),   
We also measured the expression of the adipogenic regulator, PPARGγ, and the 
lipogenic gene, FASN.  Adipogenesis is the process of preadipocytes differentiating to 
mature adipocytes (Rosen et al., 1999).  This process is regulated by the transcription 
factor PPARγ, and there is evidence that BPA may activate this adipogenic regulator 
(Chen et al., 2009a, Grun et al., 2006).  Fatty acid synthase (FASN) is a large multi-
enzyme complex responsible for the synthesis of long-chain fatty acids (Sul et al., 
2000).  If BPA was to increase the expression of one or both of these genes, it would 





Adiposity can increase through adipocyte expansion (hypertrophy), proliferation 
(hyperplasia), or a combination of both.  The number of adipocytes remains mostly 
constant throughout adulthood for both lean and obese individuals, which indicates that 
the number of adipocytes is determined at a young age (Spalding et al., 2008).  
Developmental exposure during gestation to BPA has been shown to increase birth 
weight which persist into adulthood and is associated with increased fat mass (Somm et 
al., 2009).  We believe that a possible explanation for this is that developmental 
exposure to BPA increases the proliferation of adipocyte precursors which leads to an 
increase in adipose tissue capacity later in life.  Mesenchymal stem cells (MSCs) are a 
major source for adipocyte progenitors, as well as bone and cartilage cells and are, 
therefore, a good model to study the effects that BPA has on adipocyte precursor 
proliferation.  To determine if BPA exposure could increase the number of adipocyte 
precursors, we treated mouse mesenchymal stem cells with BPA assayed the 
proliferation rate compared to controls.  An increase in proliferation of MSCs with BPA 
treatment would indicate that developmental exposure could possibly program an 
individual for increased fat mass.  
Our overall goal for this study was to determine if low levels of BPA creates an 
adipose tissue phenotype that is sensitized to expansion through increased proliferation 
of adipocyte precursors, altered energy metabolism, and changes in gene expression 
that favor obesity.  We chose to use mouse adipose tissue explants as a model rather 




the sensitivity of estrogen receptors to estrogens has been questioned (Rubin and Soto, 
2009).  This model also provided a better representation of adipose tissue in vivo. 
Methods 
Materials 
 Stock solutions of BPA (Invitrogen, Inc.) were prepared in the Campagna lab 
(Chemistry Dept., UTK) using distilled ethanol.  The ethanol was distilled to prevent 
contamination with additional estrogenic compounds leaching from the plastic bottles.  
The mouse mesenchymal stem cells were obtained from Invitrogen Life Technologies, 
Inc. (Gaithersburg, MD) and were isolated from the bone marrow of C57BL/6 mouse at 
≤ 8 weeks after gestation.  DMEM/F-12 media, Phenol-free DMEM and fetal bovine 
serum (FBS) were also obtained from Invitrogen Life Technologies, Inc.  All quantitative 
PCR (QPCR) primers were predesigned QuantiTect, and the primers and master mix 
were obtained from Qiagen, Inc. (Valencia, CA). 
Adipose tissue explants and treatment 
 Perigonadal white adipose tissue (pWAT) was harvested from 16 surplus BXD 
recombinant inbred mice and pooled together in phenol-free DMEM (Invitrogen) 
supplemented with 10% charcoal-stripped FBS to minimize endogenous estrogen 
exposure.  The adipose tissue was cultured in glass plates to prevent outside sources of 
BPA.  After 24 hours, the adipose tissue was split into six treatment groups plus a 




10nM E2, and 10nM E2 + 10nM BPA.  The tissue was pooled together and split into 
treatment groups to avoid confounding effects.  After an additional 24 hours of 
treatment, the tissue was snap frozen and pulverized using a mortar and pestle for 
metabolic and gene expression analysis. 
Metabolomics 
Approximately 15 mg of each adipose tissue sample was weighed into 1.5 mL 
centrifuge tubes. Cold methanol (500 µL at -78oC) and the internal standards, tris (5 µL 
of 4.7mM in H2O) and benzoic acid (5 µL of 1.7 mM in H2O), were added to each tube, 
and then mixed by vortexing for 2 min. The metabolites were extracted for 30 min at 4oC 
on ice, which precipitates the enzymes, followed by centrifugation (5 min, 13.2 rpm, 
16.1 rcf, 4oC). Supernatants were split into two autosampler vials each. One vial was 
placed directly in the autosampler for analysis, and the other was frozen at -80oC for 
analysis in the opposite mode the following day.  High performance liquid 
chromatography (HPLC) was performed utilizing a quaternary pump to generate a 
gradient for the elution of compounds from the stationary phase. For all samples, 10 µL 
was injected onto the column via an autosampler cooled to 4 °C.  Eluent was directly 
introduced into the electrospray ionization (ESI) chamber of the triple quadrupole mass 
spectrometer.  Samples were analyzed using selected reaction monitoring (SRM), and 
the scan time for each SRM was 0.05 s with a scan width of 1 m/z.  Raw files for each 
sample were first processed using mzRock, and once the data set was narrowed, 
Xcalibur Quan Browser was used to visualize and manually integrate metabolite peaks 




RNA isolation and quantitative PCR 
 Total RNA was extracted from adipose tissue using the RNeasy™ Lipid Tissue 
Mini Kit (Qiagen, Inc.).  The RNA quality and concentration were assessed using the 
Nanodrop™ 2000 spectrophotometer (Thermo Scientific, Inc.).  We reverse transcribed 
500ng total RNA using the iScript™ cDNA synthesis kit (Bio-Rad) which uses a 
modified MMLV-derived reverse transcriptase and a combination of oligo(dT) and 
random hexamer primers.  The relative expression of transcripts coding for mouse Tnfa 
(tumor necrosis factor alpha), Il6 (interleukin-6), Fasn (fatty acid synthase), and Pparg 
(peroxisome proliferator-activated receptor gamma) were measured by quantitative real-
time PCR (QPCR) using a CFX96™ Real-Time PCR Detection System (Bio-Rad) and 
were normalized using the housekeeping gene hypoxanthine guanine phosphoribosyl 
transferease (Hprt).  All samples were analyzed in triplicate.  We quantified the 
expression using the QuantiTect SYBR Green PCR kit and QuantiTect Primer Assays 
(Qiagen, Inc.), and relative gene expression was determined using the ∆∆Ct method 
and the Relative Expression Software Tool (REST) (Pfaffl et al., 2002).   
Proliferation Assay 
Mouse mesenchymal stem cells (MSCs) were plated in a 96-well culture plate at 
a density of ~5,000 cells per well and grown in DMEM/F-12 media.  The cells were 
allowed to attach and grow for 24 hours, then the media was replaced containing the 
one of the following: vehicle control (EtOH), 1nM BPA, 10nM BPA, 1µM BPA, 10nM E2, 




proliferation was measured using the CellTiter 96 AQueous One Solution Cell 
Proliferation Kit (Promega).  Briefly, the AQueous One Solution contains an MTS 
tetrazolium compound which is reduced by living cells to a soluble, colored formazan 
product.  This product’s absorbance can be measured at 490nm and is directly 
proportional to the number of living cells in culture. 
Statistical analysis 
 The QPCR data were analyzed using REST which uses a mathematical model 
based on the correction for exact PCR efficiencies and the mean threshold value (Ct) 
deviation between treatment groups and the control group.  The expression ratios were 
then tested for significance using a Pair Wise Fixed Reallocation Randomisation Test©.  
Differences in proliferation were analyzed using one-way analysis of the variance 
(ANOVA), and once significance was determined, post hoc tests (t-tests and LSD) were 
performed. 
Results 
 Adipose tissue explants were treated with BPA or estradiol for 24 hours.  
Following treatment, we analyzed the gene expression of some inflammatory markers 
as well as lipogenic/adipogenic genes.  Our data suggest that exposure to BPA 
increases expression of inflammatory cytokines (Figure 3-1).  There were statistically 
significant (p<0.05) increases in Tnfa expression at 10nM and 1µM concentrations and 
significant increases in Il-6 at the 1µM dose.  Tnfa was increased 2.2-fold and 1.98-fold 





Figure 3-1.  QPCR results for selected genes in mouse adipose tissue explants.  
Data were analyzed using REST and results are expressed as means ± SEM.  (*) 




in the 10nM treatment.  There were also significant increases in the expression of Fasn 
at 10nM and 1µM concentrations (1.79-fold and 2.98-fold, respectively), which would 
suggest a possible increase in lipogenesis activity.  Pparg expression was unchanged, 
indicating that BPA is not enhancing adipogenesis.  However, BPA may possibly 
increase the activity of Pparg without affecting its expression.  Estradiol did not appear 
to alter the expression of any of the genes.  Our sample size was small (n=4) and could 
explain a lack of significant results at additional treatments, however these results are 
consistent with experiments previously conducted in our lab as well as by others (Yan et 
al., 2008).  
Technical advances in recent years have advanced the ability to use global 
metabolomics to query changes in profiles of small molecule metabolites in serum and 
tissues.  It has been proposed that BPA alters adipose tissue energy metabolism which 
leads to an increase in adipose mass (Chen et al., 2009b).   After the adipose tissue 
explants were treated with BPA for 24 hours, metabolites were extracted from the tissue 
and analyzed using mass spectrometry.  The metabolite ratios were calculated after 
correcting ion counts for mass and signal difference.  The data shown represent ratios 
of select metabolites in treated vs. control adipose tissue.  Due to the small sample size, 
there were no statistically significant differences between any treatments and control, 
however there was a trend for increased glycolytic and TCA cycle intermediates with 
BPA treatment, which are important pathways in energy metabolism (Figure 3-2).  






Figure 3-2.  Metabolic profiling of BPA-treated adipose tissue.  LC-MS/MS was 
used to measure metabolite levels in white adipose tissue treated with various 




Mouse mesenchymal stem cells (MSCs) were treated with BPA or estradiol for 24 or 48 
hours to analyze the effect on proliferation.  We believe that in utero and perinatal 
exposure to BPA can possibly “program” a person to be obese by increasing 
proliferation of adipocyte precursors which would increase the adipose capacity later in 
life.  The CellTiter 96 AQueous One Proliferation Assay was used which measures the 
formation of formazan from a tetrazolium compound and is correlated with the number 
of viable cells in culture.  We found that all three concentrations of BPA used modestly 
but significantly increased proliferation (1.18-1.21-fold increase, p<0.05) of MSCs at 
both 24 and 48 hours (Figure 3-3).  The estradiol treatment did not increase proliferation 
after 24 hours, but it did increase proliferation similar to BPA after 48 hours.  The 
combination of BPA and estradiol did not have a significant effect on proliferation. 
Discussion 
 To start to study the effects that BPA has on adipose tissue development and 
function, we began by using in vitro and ex vivo models.  We used a wide range of 
concentrations of BPA ( low nM – low µM) because the effects of BPA are often non-
monotonic (Ben-Jonathan et al., 2009).  Just because there is an effect at a specific 
dose doesn’t mean that effect is going to be exacerbated at higher doses, and vice 
versa.  Traditional toxicological studies generally take a “dose makes the poison” 
approach, but BPA may actually have a greater effect at lower levels, in some cases.  
Since BPA is known to have estrogenic properties, we also used a 10nM concentration 
of estradiol and a combination of 10nM BPA and 10nM estradiol to compare the effects 





Figure 3-3.  Effects of BPA and E2 on proliferation of mouse mesenchymal stem 
cells.  Mouse MSCs were treated with various concentrations of BPA or E2 for 24 or 48 
hours.  Proliferation was assayed using the CellTiter 96 AQueous One Proliferation 




explants were chosen to be used because they are a better representation of adipose 
tissue in vivo, and there is evidence that the adipocyte cell line, 3T3-L1, which we 
normally use as a model of adipose tissue may underexpress ERs, which are candidate 
mediators of BPA action (Rubin and Soto, 2009). 
The gene expression data shown in Figure 3-1 indicate that the expression levels 
of the pro-inflammatory cytokines Tnfa and Il-6 are increased in some treatments of 
BPA.  The 10nM concentration of BPA significantly increased the expression of Tnfa 
and Il6 2.19-fold and 2.67-fold, respectively.  The 1µM concentration of BPA also 
significantly increased Tnfa expression by 1.95-fold.  While some of the other 
concentrations of BPA increased the expression of these cytokines, they were not 
significantly different from the control treatment, which may be a result of our small 
sample size (n=4).  We also measured the expression of Fasn and Pparg as markers of 
lipogenesis and adipogenesis, respectively.  While there was no change in expression 
of Pparg, Fasn expression increased 1.8-fold and 3-fold in 10nM BPA and 1µM BPA, 
respectively.  This increase in fatty acid synthase expression would indicate the 
possibility that BPA promotes enhanced de novo lipogenesis.   
There are some additional interesting things to take from these data.  The gene 
expression data across the doses of BPA creates an inverted ‘U’ shape curve, 
specifically for the cytokines.  The 10nM dose of BPA seems to increase the expression 
of Tnfa and Il6, yet this effect isn’t enhanced in the 100nM or 1µM dose, but, rather 
diminished.   This result is consistent with the non-monotonic effects often seen in BPA 




gene expression of any of the genes tested, however the combination treatment of 
10nM BPA and 10nM estradiol seemed to attenuate the effects seen in the 10nM BPA 
treatment alone.  This could reflect a competition between the two molecules for the 
same receptor(s), possibly ERs. 
Along with our collaborator, Dr. Shawn Campagna, we performed global 
metabolic profiling using small molecule metabolic mass spectrometry to query changes 
in metabolite pools from adipose tissue treated with BPA.  It is believed that BPA 
mediates its action through ERs, which are now known to play a key role in energy 
metabolism (Chen et al., 2009a, Gao et al., 2007).  Disruption of adipose energy 
balance has been proposed as a mechanism through which BPA increases adipose 
mass (Chen et al., 2009b).  The data presented in Figure 3-2 represent ratios of 
glycolytic and TCA cycle metabolites in treated vs. control adipose tissue; ratios were 
calculated after correcting ion counts for mass and signal differences.  These data 
indicate a trend for increasing doses of BPA to alter adipose energy metabolism, 
particularly intermediates of glycolysis.  Due to the method used, traditional statistical 
methods were not used to analyze the metabolomics data, rather we looked at the fold-
change: a fold-change of 1.5 or greater was considered interesting.  Once again there is 
no monotonic response to increasing BPA concentration, but changes to metabolites 
spread throughout doses in both glycolytic and TCA cycle intermediates.  The 1µM 





Glucose is broken down via glycolysis into 2 molecules of pyruvate which then 
enter the mitochondria, are converted to acetyl-CoA, and enter the tricarboxylic acid 
(TCA) cycle which forms important reducing agents necessary to produce energy.  
However, intermediates of the TCA cycle, specifically citrate, can be exported out of the 
mitochondria to the cytosol, converted to acetyl-CoA, and used for fatty acid synthesis 
(Wakil et al., 1983).  We believe that the increase in glycolytic and TCA cycle 
intermediates seen in some of the BPA treatments may be an indication that BPA 
increases glycolysis and the TCA cycle which leads to increased fatty acid synthesis.  
This would be consistent with our finding that BPA may increase fatty acid synthase 
expression, especially in the 1µM BPA treatment.  To determine if BPA alters adipocyte 
energy metabolism in a way that promotes de novo lipogenesis, a metabolic flux 
experiment must be conducted.  Metabolic flux profiling allows the tracking of labeled 
isotopes into specific metabolic pathways 
To determine if developmental exposure to BPA could possibly increase the 
number of adipocyte precursors, we assayed the proliferation of mouse MSCs treated 
with various concentrations of BPA.  The data in Figure 3-3 show that all three BPA 
treatments (1nM, 10nM, 1µM) significantly increased the proliferation of MSCs 
compared to control (p=0.013, 0.032, 0.038, respectively) after 24 hours of treatment.  
There is one less BPA treatment in this experiment due to spacing issue in the 96-well 
plate; we omitted the 100nM because we were more interested in the low nanomolar 
effects and comparing them to the 1µM treatment, which appeared to be having the 




estradiol treatment had now increased proliferation of the MSCs.  There is evidence that 
BPA may mediate its effects in two different ways.  First, it may elicit a rapid response 
via an interaction with ncmERs.  It may also then elicit a slower, prolonged response via 
an interaction with classical ERs (Alonso-Magdalena et al., 2005).  Our data may 
support these findings.  The increase in proliferation seen in the first 24 hours only 
occurs in cells treated with BPA (possibly via ncmERs).  The increase seen after 48 
hours also occurs in cells treated with estradiol, which would indicate a slower response 
via the classical ERs.  Once again, the cells treated with both BPA and estradiol did not 
show any change in proliferation rate compared to control, which would further indicate 
a competition between the molecules. 
In summary, we have shown that BPA can increase the expression of important 
inflammatory cytokines in adipose tissue.  Inflammation plays an important role in a 
number of the comorbidities associated with obesity, and BPA will only exacerbate the 
vicious circle of inflammation and obesity.  We also showed that BPA may increase 
glycolysis and the TCA cycle which leads to enhanced de novo lipogenesis.  These 
findings go hand-in-hand with our finding that some concentrations of BPA increase 
expression of fatty acid synthase.  Finally, we also showed that BPA can increase the 
proliferation of MSCs, thus increasing the number of adipocyte precursors and 
increasing the fat potential later in life.  These findings are interesting, however the 
experiments do not represent the likely route of exposure in humans.  To truly study the 
effects that BPA has on adipose tissue, we must look at the effects it has in the context 





CHRONIC EXPOSURE TO BISPHENOL A IN JUVENILE MICE AND THE 
EFFECTS ON ADIPOSE FUNCTION AND METABOLISM 
Introduction 
  There have been some studies that have shown that BPA has adverse effects in 
vivo, but at very high doses (Snyder et al., 2000, Kwon et al., 2000).  BPA has been 
detected in the urine of over 92% of the population, and higher BPA levels were 
associated with cardiovascular disease and type II diabetes, but these results do not 
prove causality (Melzer et al., 2010).   A small number of studies have shown that BPA 
affects the metabolism, insulin sensitivity, and adiposity of mice or rats exposed in utero 
(Alonso-Magdalena et al., 2010, Somm et al., 2009).  These findings are extremely 
worrisome and show that BPA can have adverse effects on developing life.  An analysis 
of the 2003-04 NHANES data found that children ages 6-11 had the highest intake of 
BPA based on bodyweight (Lakind and Naiman, 2008), and children obviously continue 
to develop after birth and have important developmental periods through puberty.  In 
fact, this time period is a critical time for adipose tissue development in which both 
adipocyte hyperplasia and hypertrophy can occur (Spalding et al., 2008).  Therefore, 
BPA exposure during early childhood through puberty could have similar effects to 




 There are a number of methods to administer BPA to mice (osmotic pump, 
injection), but the most likely route of exposure in humans is food and drink.  Once 
ingested, BPA can be metabolized in the liver to the conjugated form Bisphenol A-
glucuronide, but it can also be deconjugated throughout the body (Ginsberg and Rice, 
2009, Nishikawa et al., 2010).  Complex chemistry can take place in the body and, 
therefore, adding BPA to the drinking water or food of the mice is the most relevant 
method of exposure, however, this method makes measuring daily intake much more 
difficult. 
 We added BPA to the drinking water of C57BL/6 and DBA/2J mice at three 
concentrations (50nM, 500nM, and 5µM) as well as vehicle control starting at four 
weeks of age.  They were weighed weekly, and glucose tolerance tests were performed 
at 8-9 weeks of age.  Mice were sacrificed at 11 weeks of age and gonadal fat pads 
were dissected for gene expression profiling, metabolomics analysis, and adipocyte 
sizing.  Blood was also collected for additional assays.  We also had additional mice 
that were treated with BPA for 6 more weeks on a high fat diet  These mice were 










 C57BL/6J and DBA/2J mice were obtained from The Jackson Laboratory (Bar 
Harbor, ME).  The mice were housed and maintained in the Animal Facility and Office of 
Laboratory Animal Care in Walters Life Sciences Building at the University of 
Tennessee.  Mice received a standard chow diet and water ad libitum.  The housing 
conditions were maintained at 70 ± 2 °F and 40-60% humidity. These stocks were used 
to propagate offspring for this study.  Sixty-four mice (32 males and 32 females) of each 
strain were weaned at four weeks of age and randomized to a treatment group to avoid 
litter effect.  These mice were housed in special BPA-free polypropylene cages, and 
water was provided in glass bottles to limit exposure to BPA or other estrogenic 
compounds from the environment.  BPA was administered to the mice via drinking 
water, which was available ad libitum, at the concentrations of 50nM, 500nM, or 5µM.  
The control groups received distilled ethanol, which was used to dissolve the BPA, at a 
dose equal to the highest concentration of BPA.  The mice were weighed weekly.  At 11 
weeks of age, mice were fasted for ~5 hours and sacrificed using CO2 asphyxiation and 
cervical dislocation.  The perigonadal fat pads were dissected and blood was collected 
to measure fasting insulin levels.  A portion of the fat pad was put in RNAlater for RNA 
extraction, a portion was put in 4% paraformaldehyde for sectioning, and a portion was 
snap frozen in liquid nitrogen for metabolomics analysis.    All protocols were approved 




Glucose Tolerance Tests 
 At between 8 and 9 weeks of age (14 and 15 for mice on high-fat diet), mice 
were fasted for ~5 hours and injected intraperitoneally with glucose (1mg/g bw).  Blood 
was collected from the tail vein at 0, 15, 30, 60, and 120 mins after the injection and 
measured using a glucometer.  The measurements were averaged and plotted, and the 
area under the curve (AUC) was determined. 
RNA isolation 
Total RNA was extracted from adipose tissue using the RNeasy™ Lipid Tissue 
Mini Kit (Qiagen, Inc., Valencia, CA).  The RNA quality and concentration were 
assessed using the Nanodrop™ 2000 spectrophotometer (Thermo Scientific, Inc.) and 
Experion RNA StdSens Chips on the Experion™ automated electrophoresis system 
(Bio-Rad, Hercules, CA) to ensure excellent quality.  RNA samples were stored at -80ºC 
until needed.   
Expression profiling 
 RNA from 24 male mice (6 500nM BPA and 6 Control per strain) was sent to 
McGill University and Génome Québec Innovation Centre for gene expression profiling 
using Illumina BeadArray™ technology.  Total RNA (500ng) was amplified, synthesized 
to cDNA, and hybridized to the MouseWG-6 v2 Expression BeadChip (Illumina, Inc.).  






 We reverse transcribed 500ng total RNA using the iScript™ cDNA 
synthesis kit (Bio-Rad) which uses a modified MMLV-derived reverse transcriptase and 
a combination of oligo(dT) and random hexamer primers.  The relative expression of 
transcripts coding for select genes were measured by quantitative real-time PCR 
(QPCR) using a Quantitect primers on a CFX96™ Real-Time PCR Detection System 
(Bio-Rad) and were normalized using the housekeeping gene Hprt.  The genes 
measured included Fasn, Lep, Pparg, Estrogen receptor alpha (Esr1), Adiponectin 
(Adipoq), Estrogen related receptor gamma, (Esrrg), Paternally expressed gene 3 
(Peg3), Serpine1, Calcium and integrin binding protein 2 (Cib2), Copine 8 (Cpne8), Gap 
junction alpha 5 (Gja5), Lactate dehydrogenase (Ldhd), and Thrombospondin 2 
(Thbs2).  We quantified the expression using the QuantiTect SYBR Green PCR kit and 
Primer Assays (Qiagen, Inc.), and relative gene expression was determine using the 
∆∆Ct method with the Relative Expression Software Tool (Pfaffl et al., 2002). 
Luminex analysis of adipokine levels 
 Adipose tissue concentrations of insulin, leptin, resistin, IL-6, TNFα, monocyte 
chemotactic protein 1 (MCP-1), and plasminogen activator inhibitor 1 (PAI-1) were 
analyzed by a multiplexed flow cytometric assay using a mouse serum adipokine 
Milliplex® map kit (MADPK-71K, Millipore, Billerica, MA) on a Luminex® 200 system 
(Luminex Inc., Austin, TX).  The multiplexed assay had intra- and inter-assay variation 




assay was measured in pg/mL and normalized by measuring the total protein using a 
BCA protein assay (Thermo Scientific) giving a final measurement of pg/µg total protein. 
Serum insulin and adiponectin assays 
 Blood samples were collected at the time of sacrifice after a 5 hour fast and 
centrifuged at 4ºC for 15 minutes at 2,000 x g.  Serum aliquots were stored at -80ºC. 
Fasting serum insulin levels were measured using a commercially available ultra 
sensitive mouse insulin ELISA kit (Crystal Chem Inc., Downers Grove, IL).  Serum 
adiponectin levels were measured using a commercially available mouse adiponectin 
enzyme immunoassay kit (SPI-bio Bertin Pharma, Montigny le Bretonneux, France). 
Histological analysis of adipocyte size 
 A portion of the perigonadal fat pad was fixed for 24 hours in 4% 
paraformaldehyde then washed in PBS.  The samples were embedded in paraffin, cut 
into 5µm sections, and stained with hematoxylin and eosin.  Adipocyte size was 
measured using a previously established method (Chen and Farese, 2002).  Briefly, the 
tissue sections were viewed at 10X magnification, and images were obtained.  The 
illumination of the images was adjusted using CellProfiler cell image analysis software 
(www.cellprofiler.org).  After the illumination was adjusted, the images were converted 
to a binary image in ImageJ (NIH; rsbweb.nih.gov/ij/) using the following commands: 
Gray Mode and Threshold.  The binary images were further adjusted using Despeckle, 




measured using the “Analyze particles” command.  Approximately 200 adipocytes per 
mouse were measured. 
Metabolomics 
Approximately 15 mg of each adipose tissue sample was weighed into 1.5 mL 
centrifuge tubes. Cold methanol (500 µL at -78oC) and the internal standards, tris (5 µL 
of 4.7mM in H2O) and benzoic acid (5 µL of 1.7 mM in H2O), were added to each tube, 
and then mixed by vortexing for 2 min. The samples were extracted for 30 min at 4oC on 
ice prior to centrifugation (5 min, 13.2 rpm, 16.1 rcf, 4oC). Supernatants were split into 
two autosampler vials each. One vial was placed directly in the autosampler for 
analysis, and the other was frozen at -80oC for analysis in the opposite mode the 
following day.  High performance liquid chromatography (HPLC) was performed utilizing 
a quaternary pump to generate a gradient for the elution of compounds from the 
stationary phase. For all samples, 10 µL was injected onto the column via an 
autosampler cooled to 4 °C.  Eluent was directly introduced into the electrospray 
ionization (ESI) chamber of the triple quadrupole mass spectrometer.  Samples were 
analyzed using selected reaction monitoring (SRM), and the scan time for each SRM 
was 0.05 s with a scan width of 1 m/z.  Raw files for each sample were first processed 
using mzRock, and once the data set was narrowed, Xcalibur Quan Browser was used 







Differences in body weights were analyzed using repeated measures one-way 
ANOVA and Tukey HSD post hoc test using R 2.12.0 or SYSTAT 13.  Differences in 
adiposity, glucose tolerance, adipose adipokines, serum insulin, serum adiponectin, and 
adipocyte size were analyzed using a one-way ANOVA, and post hoc tests (t-test and 
LSD) were performed once significance was determined.  Results are shown as means 
± SEM.  A p-value < 0.05 was considered significant.  Metabolomics data was also 
analyzed using ANOVA, however a change of 1.5-fold or higher was considered 
interesting and significant.  All of the QPCR data was analyzed using REST which uses 
a mathematical model based on the correction for exact PCR efficiencies and the mean 
crossing point deviation between treatment groups and the control group.  The 
expression ratios are then tested for significance using a Pair Wise Fixed Reallocation 
Randomisation Test©.   
Statistical analysis of the Illumina microarray probe profile data was performed 
using R 2.12.0. Data were processed based on detection p-values of at least 20 arrays 
out of 24 arrays less than 0.05 using Genefilter package in Bioconductor, otherwise, 
they were assumed to be low expression data and were filtered out. Quantile 
normalization was applied to the data to make intensities consistent within each array. 
The significance of gene expression was analyzed by ANOVA and empirical bayes 
statistics (ebayes) using limma package.  The differentially expressed genes with p-





Effect of BPA on body weight and adiposity 
 C57BL/6 and DBA/2J mice were exposed to BPA via drinking water after 
weaning for seven weeks, and the mice were weighed weekly beginning at 4 weeks of 
age.   There was no difference in bodyweight between any of the treatments for females 
of either strain (data not shown).  However, there was a significant difference in the 
body weight of male C57BL/6 mice treated with 50nM BPA compared to control starting 
at 7 weeks of age that persisted until the time of sacrifice (Figure 4-1).  Male C57BL/6 
mice were 1.5-2.0g heavier (10 weeks of age: 500nM = 26.1g, control = 24.3, p<0.05) 
from 7 weeks of age to the time of sacrifice.  Male DBA/2J mice treated with 500nM 
BPA were significantly heavier than control, but only near the end of the study at 10 
weeks of age (500nM = 26g, control = 25g, p<0.05).   
At the end of the study, gonadal fat pads were weighed and normalized to body 
weight to determine adiposity.  Again, there was no difference between any of the 
treatments in females of either strain (data not shown).  Adiposity was increased in the 
500nM BPA treatment approximately 25% in the C57BL/6 males compared to control 
(1.65 fat pad percentage in 500nM treatment compared to 1.32 in control, p=0.028) 
(Figure 4-2).  There was a smaller and less significant increase in adiposity of 8% in 
DBA/2J male mice treated with 500nM BPA compared to control (2.26 fat pad 






Figure 4-1.   Effects of BPA on bodyweight in male mice.  (A) C57BL/6 male mice 
and (B) DBA/2J male mice.  Mice were exposed to various doses of BPA via drinking 





Figure 4-2.  Effects of BPA on adiposity in male mice.  (A) C57BL/6 males and (B) 
DBA/2J males.  Gonadal fat pads were weighed and expressed as a percentage of 




suggest that the increase in body weight is associated with an increase in adipose 
tissue. 
Glucose tolerance tests 
 BPA has been shown to disrupt glucose homeostasis in pregnant mice as well as 
their male offspring once they reached adulthood (Alonso-Magdalena et al., 2010).  
Therefore, glucose tolerance tests were performed to determine if BPA has an effect on 
insulin sensitivity and the ability to clear glucose.  Due to the large of number of mice, 
GTTs were performed over a two week span.  There was a clear strain difference in the 
sensitivity to this assay.  Normally, following an i.p. injection of a glucose bolus, blood 
glucose levels spike and then gradually decrease over the next 2 hours.  We found that 
the DBA/2J strain had a minimal spike and returned to pre-injection levels within 30 
minutes. A previous study showed that DBA/2J mice have higher serum insulin levels 
and generally lower blood glucose levels, so these results weren’t surprising (Alexander 
et al., 2006). For this reason, we were unable to detect any difference between the 
treatments for the DBA/2J mice (data not shown).  The C57BL/6 mice had a more 
traditional response to the glucose injection.  Blood glucose measurements were 
changed from mg/dL units to mmol/L and plotted.  The area under the curve (AUC) was 
determined to assay differences in glucose tolerance.  We found that the AUC 
measurements were higher for the mice exposed to BPA in both the males and females 
of the C57BL/6 strain, however, only the 500nM treatment in the males was close to 




Figure 4-3.  Glucose tolerance test results for C57BL/6 mice treated with BPA.  Males (A, B) treated with 50nM or 
500nM BPA showed slower clearance rates compared to controls.  The difference was not as great in females (C, D).  
Results are shown as means ± SEM.  (·) p<0.1. 
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Serum insulin and adiponectin levels 
 We collected blood to measure fasting serum insulin levels to determine the 
effect that BPA has on circulating insulin levels.  Interestingly, we found no significant 
differences in the males of either strain.  However, we did see differences in the 
females.  All three treatments of BPA showed significantly higher serum insulin levels in 
female C57BL/6 mice with the 5µM treatment having the greatest difference compared 
to control (Figure 4-4).  Surprisingly, we found the opposite result in female DBA2 mice.  
All three treatments of BPA had significantly lower serum insulin levels compared to 
controls, illustrating not only a physiological difference between the two strains but a 
difference in the way each strain is affected by BPA.  Due to limited resources, some of 
the experiments and assays were only done for the specific groups that showed 
differences in adiposity, i.e. the males of the 500nM BPA treated group and control 
group.  Measurement of serum adiponectin was one of these assays.  We found that 
the serum adiponectin levels were significantly (p=0.0012) lower in 500nM BPA group of 
C57BL/6 males and were nearly significant (p=0.08) for the DBA/2J males (Figure 4-5). 
Adipose adipokine profiles of BPA treated mice 
 The quantity of six adipokines were assayed in the adipose tissue of mice 
treated with BPA using the mouse serum adipokine Milliplex® map kit on a Luminex® 
200 system.  The measurements for each adipokine were normalized using total protein 




 Figure 4-4.  Fasting serum insulin levels in mice treated with BPA.  Mice were 
fasted for ~5hrs and blood was drawn at sacrifice.  Insulin was measured using a 














Figure 4-5.  Serum adiponectin levels in males treated with BPA.  Serum adiponectin 





resistin compared to the other adipokines.   There were no differences between 
treatments for MCP-1, IL-6, TNFα, or resistin.  There were also no extreme differences 
between strains for any of the adipokines.  The only adipokine that was significantly 
altered by BPA was plasminogen activator inhibitor 1 (PAI-1).  C57BL/6 males treated 
with 50nM and 500nM had approximately twice the levels of PAI-1 compared to controls 
(p=0.018, 0.012 for 50nM and 500nM, respectively) (Figure 4-6).  We also found that 
the 500nM dose of BPA slightly increased leptin in both C57BL/6 males and DBA/2J 
males (data not shown), but the results were not significant. 
Gene expression profiling and QPCR 
 Our results indicate that male mice exposed to 500nM BPA were significantly 
fattier than their control counterparts.  To identify changes in gene expression 
associated with the increased adiposity, global gene expression profiling was performed 
for these mice on the Illumina platform (Genome Quebec Innovation Center).  Due to 
the distribution of the data and the lack of a large set of expression changes, we were 
unable to do FDR and extract q-values.  Therefore, we were conservative in selecting 
genes and used a p-value < 0.005.  We found 95 genes differentially expressed in 
C57BL/6 males and 71 genes differentially expressed in DBA/2J males.  Of all these 
genes, only 2 genes, Leptin and Heparan sulfate proteoglycan 2 (Hspg2), were 
differentially expressed in both strains.  Leptin was increased 1.45-fold and 1.41-fold 
and Hspg2 was increased 1.25-fold and 1.18-fold in C57BL/6 and DBA/2J, respectively.  





Figure 4-6.   Adipose levels of PAI-1 and Leptin in C57BL/6 males.  Adipokine 
levels were measured in adipose tissue using a Milliplex map kit and Luminex system.  





statistically significant.  The genes with the greatest significant change for each strain 
are listed below (Table 4-1 and 4-2).  There was a 2.56-fold decrease in Cytochrome 
P450 2f2 for C57/BL6 treated compared to control and a 3.85-fold decrease in 
Immunoglobulin kappa constant for DBA/2J.  Transmembrane glycoprotein NMB 
increased 1.7-fold in BPA treated C57BL/6 mice compared with control, and S100 
calcium binding protein 8 increased 1.96-fold in DBA/2J mice. 
 We also conducted QPCR for a number of genes.  We selected the adipogenic 
and lipogenic genes, Pparg and Fasn.  We also tested a number of other genes of 
interest as well as some genes of interest identified from the initial array data.   We 
found no statistically significant difference in Fasn, Pparg, Esr1, Esrrg, or Adipoq for the 
C57BL/6 males treated with BPA compared to control.  There was a slight increase in 
leptin expression, which matches with our array data, but the change was not 
statistically significant (p=0.17) (Figure 4-7).  For genes identified from the array data, 
we confirmed statistically significant increases in Peg3 (2.25-fold increase, p=0.028), 
Gja5 (1.75-fold increase, p=0.011), and Thbs2 (2.046-fold increase, p=0.005).  We also 
found a decrease in Ldhd expression (1.48-fold decrease) but the result weren’t 
statistically significant (p= 0.09). 
 For the DBA/2J mice, there were also no significant changes in the expression of 
Fasn, Pparg, Esr1, Essrg, or Adipoq.  There was, however, a 1.40-fold increase in the 















Table 4-1.  Top genes differentially expressed in C57BL/6 male mice treated 
with 500nM BPA compared to control.
Gene symbol Gene name Fold change p-value 
Gpnmb Transmembrane glycoprotein NMB 1.7 0.0028
Mmp12 Matrix metalloproteinase 12 1.69 0.0012
Sfrp5 Secreted frizzled-related protein 5 1.66 0.0018
Thbs2 Thrombospondin 2 1.64 0.0070
Peg3 Paternally expressed gene 3 protein 1.62 0.0048
Emp3 Epithelial membrane protein 3 1.57 0.0030
Lep Leptin 1.45 0.0018
Fbn1 Fibrillin-1 1.45 0.0020
Itih5 Inter-alpha (globulin) inhibitor H5 1.44 0.0059
Myl4 Myosin light chain 4 1.4 0.0031
Cyp2f2 Cytochrome P450 2F2 -2.56 0.0007
Tst Thiosulfate sulfurtransferase -1.89 0.0023
Net1 Neuroepithelial cell-transforming 1 -1.64 0.0002
Ldhd Lactate dehydrogenase -1.54 0.0029
Fos FBJ osteosarcoma oncogene -1.47 0.0077














Table 4-2.  Top genes differentially expressed in DBA/2J male mice treated 
with 500nM BPA compared to control. 
Gene symbol Gene name Fold change p-value 
S100a8 S100 calcium binding protein 8 1.96 0.0040
Cdkn1a Cyclin-dependent kinase inhibitor 1 1.59 0.0050
Dusp1 Dual specificity protein phosphatase 1 1.52 0.0066
Klf6 Krueppel-like factor 6 1.48 0.0015
Lep Leptin 1.41 0.0033
Vldlr Very low density lipoprotein receptor 1.35 0.0024
Serpina1b Serine peptidase inhibitor A1B 1.34 0.0033
Eif5 Eukaryotic translation initiation factor 5 1.32 0.0060
Adap2 ArfGAP w/ dual PH domains 2 1.3 0.0041
Osgin1 Oxidative stress induced growth factor 1 1.3 0.0035
Igkc Immunoglobulin kappa constant -3.85 0.0013
Cxcl13 CXC motif chemokine 13 -3.03 0.0002
Igkv5 Immunoglobulin kappa variable 5 -2.78 0.0011
Faim3 Fas apoptotic inhibitory molecule 3 -1.49 0.0045
Cyp2e1 Cytochrome P450 2E1 -1.41 0.0011





Figure 4-7.   QPCR results for selected genes in C57BL/6 male mice.  Mice exposed 
to 500nM BPA are compared to Controls.  Results are expressed as expression ratios 
determined using the ∆∆Ct method. (*)p<0.05, (**)p<0.01. 
    * 
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Figure 4-8.   QPCR results for selected genes in DBA/2J male mice.  Mice 
exposed to 500nM BPA are compared to Controls.  Results are expressed as 
expression ratios determined using the ∆∆Ct method. (*)p<0.05, (**)p<0.01. 
* 
   ** 




we confirmed significant changes in the expression of Cpne8 (1.39 decrease, p=0.018), 
Ldhd (1.82 decrease, p=0.008), and Thbs2 (1.6 decrease, p=0.04). 
Adipocyte size measurement 
 To determine if BPA exposure has an effect on adipocyte expansion, we used a 
portion of the gonadal fat pad for histological analysis and measured average adipocyte 
differences between mice exposed BPA versus control mice.  We used a variation of 
the method previously described (Chen and Farese, 2002) which uses computer image 
analysis software to measure adipocyte size.  The image conversion process results in 
some small artifacts, therefore, we set a lower limit threshold that would allow us to 
measure approximately 200 adipocytes per animal/slide.  Once again, only the males 
treated with 500nM or control were used for histological analysis.  We found that the 
males treated with 500nM had significantly larger adipocytes compared to control 
(Figure 4-9).  C57BL/6 males treated with 500nM BPA had an average adipocyte size of 
10859 µm2 compared to 9143 µm2 in control (p=0.048).  The DBA/2J males showed 
similar results with an average adipocyte size of 13392 µm2 and 10081 µm2 in 500nM 
BPA treatment and control, respectively (p=0.041). 
Metabolomics 
 A portion of the gonadal fat pad was subjected to global metabolic profiling to 
determine if in vivo exposure to BPA changes adipose tissue metabolism, which could 
explain the changes in adiposity.  We previously used this technique in adipose tissue 





Figure 4-9.   Effects of BPA on adipocyte size.  Mice treated with 500nM BPA are 




intermediates, indicating a change in adipose tissue energy metabolism.  We expected 
to see more subtle yet similar results for our in vivo treatment.  We only used  male 
mice to measure the changes in metabolite levels since the changes in adiposity were 
seen in males.  Due to the variance in metabolite measurements from mouse to mouse, 
we looked for metabolites with 1.5-fold difference between a BPA treatment and control.  
We did not see many large changes in glycolytic metabolites or TCA cycle metabolites.  
There was a decrease in the glycolytic metabolites fructose-6-phosphate (50nM = -1.89-
fold, 500nM = -2.35-fold) and phosphoenolpyruvate (5µM = -1.55-fold).  Citrate is the 
metabolite in the TCA cycle that can be shuttled out of the mitochondria and used for 
fatty acid synthesis, and we saw a decrease in this metabolite as well (50nM = -2.12-
fold, 500nM = -2.01-fold) (Figure 4-10). 
Discussion 
 We studied the effects that chronic exposure to BPA has on adipose tissue in an 
organism using two different inbred strains of mice, C57BL/6 and DBA/2J.  These are 
the parental strains for the BXD recombinant inbred line, and both are routinely used in 
cardiovascular and obesity studies (Campen et al., 2004, Gallou-Kabani et al., 2007).  
We chose our doses of BPA based on previous research (Somm et al., 2009).  Somm 
and colleagues used a treatment of 1 mg/L BPA in the drinking water of pregnant 
Sprague-Dawley rats and found increased birth weight, as well as increased adiposity 
and adipogenesis in females at weaning.  The highest concentration that we used, 5µM, 




















Figure 4-10.  Glycolytic and TCA cycle intermediates levels in adipose tissue.  
Fructose-6-phosphate and citrate were the two intermediates from glycolysis and 
TCA cycle, respectively, with the greatest fold-change.  Results are shown as 




are larger than mice, we chose to use the smaller, as well as more biologically relevant, 
concentrations of 500nM and 50nM BPA.  Based on an estimated daily intake of 6-7mL   
water for each mice, we estimated that the daily intake of BPA for the 5µM, 500nM and 
50nM treatment was 350µg/kg bw/day, 35µg/kg bw/day, and 3.5µg/kg bw/day, 
respectively.  This estimation was determined based on weekly water consumption and 
does not account for spillage, therefore, the actual intake may be slightly lower than the 
estimation.   All three concentrations are lower than the No-observed-adverse-effect-
level (NOAEL) of 50mg/kg bw/day, and the low and middle concentration are below the 
acceptable daily intake (ADI) for humans of 50µg/kg bw/day set by the EPA 
(http://www.epa.gov/iris/subst/0356.htm). 
 We found no difference in bodyweight or adiposity for females exposed to BPA 
compared to control.  The results in Figure 4-1 and 4-2 show, however, that we did find 
differences in males for both strains.  In C57BL/6, males treated with lowest dose of 
BPA were significantly heavier beginning at 7 weeks of age and continuing throughout 
the study, but the only difference in adiposity occurred in the 500nM treatment.  It’s 
possible that the B6 males treated with 50nM BPA had greater fat gain in other depots, 
however we only dissected gonadal fat pads which are representative of abdominal fat 
in humans.  DBA/2J males treated with 500nM were significantly heavier than controls 
by the time of sacrifice.  They also had increased adiposity, however, the results were 
not statistically significant (p=0.08).  There was a clear difference between the effects 
seen in males and females.  Because BPA is an endocrine disruptor and mimics 




treatments.  It was also not surprising to find that the 500nM was the only treatment that 
increased adiposity due to the lack of monotonic results in many other studies.  Based 
on these results, we decided to focus on males for a number of the other experiments, 
and specifically the 500nM treatment of BPA. 
 Not surprisingly, we saw a significant difference in fasting blood glucose levels 
between the sexes.  What was surprising was the great difference between the strains.  
The blood glucose levels in DBA/2J mice barely spiked after injection (data not shown), 
indicating an ability in the DBA/2J strain to quickly regulate blood glucose levels.  
C57/BL6 mice reacted as expected (Figure 4-3), and we found that male mice treated 
with 50nM and 500nM cleared glucose from the blood slower than control, but the 
results were no significant.  We also measured fasting insulin levels to determine if BPA 
may affect insulin synthesis and secretion.  Surprisingly, we found significant difference 
in females for both strains, but opposite results (Figure 4-4).  C57BL/6 females had 
higher fasting insulin levels in all treatments compared to control, but the DBA/2J 
females had lower serum insulin levels in all treatments.  There were no significant 
differences in the males for either strain.  These results, once again indicate a 
physiologically difference between the two strains, and that the two strains may be 
having different physiologically responses to BPA. 
 Low nanomolar concentrations of BPA have been shown to inhibit secretion of 
adiponectin  from adipose tissue (Hugo et al., 2008).  We used an adiponectin EIA kit to 
measure serum adiponectin levels in males treated with 500nM BPA or control.  Our 




2008).  Adiponectin levels were significantly lower in the serum of mice exposed to 
500nM BPA (Figure 4-5).  The decreases were greater and more significant in C57BL/6 
mice than DBA/2J.  We also measured the levels of other adipokines in the adipose 
tissue of the male mice treated with BPA using the mouse serum adipokine Milliplex 
xmap kit on the Luminex platform.  While the Luminex system gave us a large amount 
of data, we only found a significant difference in one analyte, PAI-1.  C57BL/6 male 
mice treated with 50nM or 500nM BPA had significantly higher levels of PAI-1 
compared to control (Figure 4-6).  PAI-1, or plasminogen activator inhibitor 1, is a serine 
protease inhibitor, and higher serum levels of PAI-1 have been detected in patients with 
coronary heart disease (Kohler and Grant, 2000). It has also been linked to obesity and 
insulin resistance (Juhan-Vague and Alessi, 1997).  PAI-1 is also known as Serpine1, 
and the expression of many Serpines have been found to be elevated in fatty chickens 
(Larry Cogburn, personal communication).  Interestingly, the elevated PAI-1 levels were 
found in the mice that were significantly heavier (50nM) and fatter (500nM) compared to 
control. 
 We conducted expression profiling for the male mice treated with 500nM BPA 
and control to try to identify the genes that were differentially expressed, which would 
shed some insight on the molecular basis of BPA increasing adiposity.   The list of 
genes differentially expressed between treatments was fairly small, which prevented us 
from performing FDR and extracting q-values.  The mice were treated with lower doses 
and at a less critical time of development compared to perinatal development, which 




expression was higher in treated which is consistent with our finding that the 500nM 
treatment increased adiposity.  There were some interesting genes identified.  One of 
particular interest was Peg3, or paternally expressed gene 3.  We found that Peg3 was 
increased 1.62-fold in C57BL/6 males treated with BPA (p=0.0048), and these results 
were validated using QPCR (2.25-fold increase).  A past study showed that a targeted 
mutation in Peg3 led to increased body fat in mice and is a candidate gene for 
regulation of fat content (Curley et al., 2005).  It has also been shown to regulate energy 
during gestation.  Peg3 expression has also been shown to activate the  TNF/NF-κB 
pathway in kidney cells (Nogueira et al., 2009).  Perhaps BPA increases Peg3 
expression leading to disruption of energy homeostasis in adipose tissue, promoting 
increased fat mass and inflammation.  We also found a few Cytochrome P450 genes 
that were down-regulated in the treated mice for both C57BL/6 and DBA/2J.  We also 
found that Serpinea1b expression was increased in DBA/2J males treated with BPA 
which is consistent with the finding that Serpines have higher expression in fattier 
chickens. 
 It is thought that obesity proceeds through both expansion of adipocytes and 
proliferation of preadipocytes, however adipocyte hypertrophy occurs first (Spalding et 
al., 2008).  Adipocyte size is also positively correlated with insulin resistance and 
inflammation (Skurk et al., 2007).Therefore, we believed that if BPA increased adiposity 
and inflammation, we would see a difference in adipocyte size.  We found that the 
adipocytes of mice treated with 500nM BPA were slightly larger than those of mice 




these results were statistically significant (Figure 4-9).  The changes were subtle and 
not easily visible to the naked eye.  There is evidence that smaller adipocytes are more 
insulin sensitive than the larger adipocytes, and there is a greater population of smaller 
adipocytes in leaner individuals (Skurk et al., 2007).  Due to the image conversion 
method, we were only able to measure the 200 largest cells per frame and could not 
measure the smaller adipocytes. 
 The changes in metabolite levels in mice exposed to BPA compared to control 
were more subtle than the changes observed in the adipose tissue explants, which was 
not surprising.  However, what was somewhat surprising was to find that the levels of 
some glycolytic and TCA cycle intermediates were lower in treated mice, which was the 
opposite of our findings in the ex vivo study (Figure 4-11).  Fructose-6-phosphate, an 
intermediate of glycolysis, was decreased in mice treated with 50nM and 500nM BPA 
(1.89-fold and 2.35-fold change, respectively.  Citrate, the TCA cycle intermediate that 
is used in lipogenesis, was also decreased for these treatments (2.12-fold and 2.01-fold 
change, respectively).  A low metabolite pool can indicate that the metabolic pathway is 
decreased or it could mean that the metabolic pathway is so active that the metabolites 
do not have a chance to form a pool before being used in another pathway.  It’s 
possible that the metabolites of glycolysis and the TCA cycle were able to pool in the 
adipose tissue explants, however in the live mice the metabolites get used by another 
pathway much more rapidly.  If this is the case, then this would indicate that glycolysis 
and the TCA cycle are still increased, and perhaps citrate is being shuttled out of the 











Figure 4-11.  Diagram of the TCA cycle and citrate shuttle.  Pyruvate from 
glycolysis enters the mitochondria to enter the TCA cycle.  An intermediate, 
citrate can be shuttled to the cytosol to be converted to acetyl-CoA and begin 
fatty acid synthesis (Garrett and Grisham. Biochemistry. 2nd Ed.  1999). 
Figure 4-11. Diagram of the TCA cycle and citrate shuttle. Pyruvate from glycolysis 
enters the mitochondria to enter the TCA cycle. An intermediate, citrate can be shuttled 
to the cytosol to be converted to acetyl-CoA and begin fatty acid synthesis (Garrett and 





There are definitely genetic and phenotypic differences between sex and strain, 
and these differences appear to affect the impact that BPA has on an individual.  The 
BPA studies to date for adiposity are few, and almost all have focused on the effects of 
in utero exposure.  We essentially modeled childhood exposure, independent of any 
“programming” that may occur during embryonic development.  We showed a modest 
but significant increase in fatness with consumption of a reasonable level of BPA over a 
seven week period.  The bodyweight and adiposity of the males were increased for both 
C57BL/6 and DBA/2J treated with BPA.  The serum insulin levels were unchanged in 
the males but were changed in females for both strains, however BPA had an opposite 
effect in each strain.  A different set of genes were differentially expressed between 
C57BL/6 and DBA/2J.  The adipocytes were slightly larger for both strains exposed to 
BPA, and some glycolytic and TCA cycle intermediates were lower in treated indicating 
that those metabolic pathways may have been more active.  Taken together these data 
indicate that BPA disrupts energy homeostasis and gene expression in adipose tissue 
in way that promotes weight gain, however the severity of its action is unclear.  Our 
results imply that BPA consumed in children may contribute to childhood obesity by 
promoting adipocyte expansion, independent of any developmental effects of BPA.  In 
conclusion, we showed that BPA exposure below the ADI may increase adiposity and 
promote weight gain, and although the effects are probably not as severe as those that 
occur from gestational and perinatal exposure, they can further exacerbate the effects 






 We have demonstrated that BPA can disrupt adipose tissue metabolism, gene 
expression, and endocrine function in a way that promotes weight gain, however, the 
effects were modest and not dose-dependent.  These non-monotonic results are 
consistent with other results commonly seen in studies of endocrine disrupting 
chemicals (Grun and Blumberg, 2009a, Vandenberg et al., 2009).  The method of 
delivery was also a possible source of variability.  Controlling the dosage is much more 
difficult when administering orally via drinking water due to the variability of water intake 
between animals.  Our estimates of daily intake are based on daily water intake per 
cage and don’t account for spillage, so it is possible that some of the treatments were 
lower from cage to cage.  However, this is necessary to replicate the most likely route of 
exposure in humans. 
 A future study that is planned is to determine if BPA treatment exacerbates 
weight gain and the inflammatory effects of a high fat diet.  We conducted a preliminary 
experiment that studied the effect that a high fat diet combined with BPA exposure has 
on body weight and adiposity, and these results can be found in the appendix of this 
thesis.  The typical consumption pattern in the United States would be that of a high 
dietary fat intake coupled with significant BPA exposure, and it is quite possible that 




There are also plans to conduct a study in which we will treat pregnant mice with 
BPA via drinking water and continue treatment in the pups after birth.  Our future in vivo 
BPA studies should focus on one strain, C57BL/6.  This strain appeared to be more 
sensitive to BPA than the DBA/2J strain and is commonly used in obesity studies 
(Gallou-Kabani et al., 2007, Schreyer et al., 1998).  Humans are commonly exposed to 
low nanomolar doses, therefore, we should use a low nanomolar dose as well.  In the 
next study, we should replace the 5µM dose with a 5nM dose.  For these future studies, 
along with the measurement we performed previously (body weight, adiposity, 
adipocyte size, etc.), we should measure fasting glucose and the circulating levels of 
adipokines rather than adipokine levels in the tissue.  We should also examine the 
effects that BPA has on the liver and pancreas.  A study that combines perinatal BPA 
exposure and continues treatment to adolescence would best represent the level of 
exposure to BPA in the US, especially those in lower income environments.  Those in 
lower income communities are most likely not educated on the potential dangers of 
BPA.  A study that exposed mice to low levels of BPA during gestational and perinatal 
development through adulthood would likely represent the levels of exposure for a large 
portion of humans.  
We found that BPA did not alter expression of the adipogenic regulator, PPARγ, 
however, it is possible that BPA may enhance the activity of PPARγ.  A mutation in the 
this gene that results in constitutively active PPARγ results in extreme obesity, and 
there is evidence that some endocrine disruptors affect PPARγ signaling (Ristow et al., 




study may be due to enhanced activity of PPARγ.  To study the effects that BPA has on 
PPARγ activity, we would use a PPARγ response element plasmid.  Briefly, PPRE X3-
TK-luc plasmid would be transfected into differentiated 3T3-L1s, or another cell line that 
adequately expresses PPARγ.  The cells would then be treated with doses of BPA 
ranging from 1nM to 1µM.  If BPA enhances the activity of PPARγ, the transcription 
factor will bind the PPRE resulting in luciferase expression and a light signal.  
Rosiglitazone would be used as a positive control, and the expression of luciferase 
would be proportional to the PPARγ activity.  This experiment would allow us to 
determine if biologically relevant concentrations of BPA may promote adipogenesis 
through activation of PPARγ. 
The metabolomic experiments we conducted allowed us to measure pools of 
metabolites in adipose tissue and detect changes that may be a result of BPA 
treatment.  While these experiments provide insight to the metabolic changes that occur 
as a result of BPA, they only provide a snapshot of the metabolism at the time of 
sacrifice.  To determine the rate at which these metabolites are being used or produced, 
we must conduct a metabolic flux analysis.  This type of experiment can be done using 
adherent mammalian cells, and we would use differentiated 3T3-L1s (Yuan et al., 
2008).  Cells are grown in unlabeled media for a period of time before being switched to 
media containing C-13 labeled glucose or glutamine.  Metabolites are extracted from 
the cells at various time points from 0 mins to 4 hrs.  Metabolites are measured using 
LC-MS/MS to measure the rate that a certain metabolite is produced.  In our 




before being switched to the labeled media.  The treatment would continue during the 
labeled media switch.  This would allow us to definitively determine if the increase or 
decrease in glycolytic and TCA cycle metabolites is a result of changes in these 
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Effects of Bisphenol A on Body Weight and Adiposity in Combination 
with a High Fat Diet 
  We performed a small preliminary experiment to study the effect that BPA has in 
combination with a high fat diet.  There were 8 C57BL/6 mice (4 males and 4 females) 
and 8 DBA/2J mice were exposed to 5µM BPA beginning at 4 weeks of age, as well as 
8 control mice per strain.  At 11 weeks of age, all mice were switched from standard 
chow to a high fat diet (58% fat).  Mice were weighed weekly and sacrificed at 17 weeks 
of age.  We dissected gonadal fat pads to assess adiposity.  We found that both 
C57BL/6 males and females treated with BPA were significantly heavier compared to 
control by the end of the study (37.4g vs 33.2g in males, p=0.035; 28.7g vs 24.8g in 
females, p=0.014) (Figure A-1).  There was no significant difference in the DBA/2J mice.  
We also found that both C57BL/6 males and females treated with BPA were fattier 
(6.8% vs 5.94% in males, p=0.065; 4.21% vs 2.99%, p=0.074) (Figure A-2).  The 
C57BL/6 males exposed to BPA also had significantly higher serum insulin levels 
compared to controls, but there was no difference in females (Figure A-3).  These data 
suggest that BPA may exacerbate the effects of a high fat diet and further experiments 









Figure A-1.  Bodyweight data of mice on a high fat diet treated with 
BPA.  C57BL/6 mice (above) and DBA/2J mice (below) were treated with 
5uM BPA or control from 4 weeks of age to 17 weeks of age.  They were 







Figure A-2.  Effects of BPA on adiposity in mice on a high fat diet.  Gonadal fat 
pads were dissected from C57BL/6 (above) and DBA/2J (below) and divided by total 








Figure A-3.  Serum insulin levels in mice on a high fat diet treated with BPA.  
Insulin levels are higher in C57BL/6 males treated with BPA and lower in DBA/2J males 
















Table A-1.  Genes significantly changed in C57BL/6 males treated with 500nM 
BPA compared to control. 








PEG3   paternally expressed 3 (Peg3), mRNA.  1.620  0.00481 
EMP3   epithelial membrane protein 3 (Emp3), mRNA.  1.568  0.00299 
HIST1H2AI   histone cluster 1, H2ai (Hist1h2ai), mRNA.  1.491  0.00262 
LEP   leptin (Lep), mRNA.  1.449  0.00178 
FBN1    1.447  0.00204 

























MYO1G   myosin IG (Myo1g), mRNA.  1.305  0.0011 
PFTK1   PFTAIRE protein kinase 1 (Pftk1), mRNA.  1.303  0.00242 


















PQLC3   PQ loop repeat containing (Pqlc3), mRNA.  1.264  0.00478 
       




       
       
Gene symbol  Gene name  Fold change  p‐value 
CSNK1G2   casein kinase 1, gamma 2 (Csnk1g2), mRNA.  1.249  0.00204 
















NECAP2   NECAP endocytosis associated 2 (Necap2), mRNA.  1.218  0.00479 


















LHX6    1.180  0.00277 
LEPRE1   leprecan 1 (Lepre1), transcript variant 3, mRNA.  1.179  0.00126 
NFKB2    1.176  0.0038 







FLOT1   flotillin 1 (Flot1), mRNA.  1.169  0.0017 










ZFP473   zinc finger protein 473 (Zfp473), mRNA.  1.138  0.00375 
STRN    1.120  0.00463 
RBMY1A1   RNA binding motif protein, Y chromosome, family 1  ‐1.125  0.00453 




       








4930487N19RIK    ‐1.157  0.00319 




CML1   camello‐like 1 (Cml1), mRNA.  ‐1.179  0.00323 
MYOG   myogenin (Myog), mRNA.  ‐1.188  0.00142 
BAG4   BCL2‐associated athanogene 4 (Bag4), mRNA.  ‐1.206  0.00245 
5530401J07RIK    ‐1.223  0.00269 
RAF1    ‐1.224  0.00493 
MYO1B   myosin IB (Myo1b), mRNA.  ‐1.227  0.00425 




NKG7   natural killer cell group 7 sequence (Nkg7), mRNA.  ‐1.240  0.00341 







TTC33   tetratricopeptide repeat domain 33 (Ttc33), mRNA.  ‐1.276  0.00439 




SCL33870.2_144    ‐1.299  4.00E‐05 




LUC7L2   LUC7‐like 2 (S. cerevisiae) (Luc7l2), mRNA.  ‐1.319  0.00177 
SCL000408.1_6    ‐1.371  0.00099 





















Table A-2.  Genes significantly changed in DBA/2J males treated with 500nM BPA 
compared to control 
Gene symbol  Gene name  Fold change  p‐value
S100A8   S100 calcium binding protein A8 (calgranulin A) (S100a8), mRNA. 1.963  0.00401
KLF6   Kruppel‐like factor 6 (Klf6), mRNA. 1.475  0.00154
LEP   leptin (Lep), mRNA.  1.411  0.00329
2310036D22RIK  1.402  5.00E‐05





HIST2H3C1   histone cluster 2, H3c1 (Hist2h3c1), transcript variant 1, mRNA. 1.306  0.00474
ADAP2   ArfGAP with dual PH domains 2 (Adap2), mRNA. 1.305  0.00414
OSGIN1   oxidative stress induced growth inhibitor 1 (Osgin1), mRNA. 1.301  0.00347
FABP9   fatty acid binding protein 9, testis (Fabp9), mRNA. 1.287  0.00303
IQGAP1  1.286  0.00076
NFIC  1.256  0.00491
JUN   Jun oncogene (Jun), mRNA.  1.255  0.00331
C130073O12RIK  1.243  0.00362


















IGSF21   immunoglobin superfamily, member 21 (Igsf21), mRNA. 1.206  0.00052
IMPAD1   inositol monophosphatase domain containing 1 (Impad1), mRNA. 1.203  0.00288
TTC14  1.202  0.00024
N6AMT1   N‐6 adenine‐specific DNA methyltransferase 1 (putative) (N6amt1), mRNA. 1.197  0.00479







HSPG2  PREDICTED:  perlecan (heparan sulfate proteoglycan 2) (Hspg2), mRNA. 1.179  0.00348
HAS2   hyaluronan synthase 2 (Has2), mRNA. 1.170  0.00407









Gene symbol  Gene name  Fold change  p‐value
LRSAM1   leucine rich repeat and sterile alpha motif containing 1 (Lrsam1), mRNA. 1.145  0.00257
IGHV1S20_K02153_IG_HEAVY_VARIABLE_1S20_37 1.142  0.00238








AOC2   amine oxidase, copper containing 2 (retina‐specific) (Aoc2), mRNA. ‐1.135  0.00483
FGD6  ‐1.139  0.00198
6030441H18RIK  ‐1.143  0.00185
TCEAL6   transcription elongation factor A (SII)‐like 6 (Tceal6), mRNA. ‐1.149  0.0045
PSMB4   proteasome (prosome, macropain) subunit, beta type 4 (Psmb4), mRNA. ‐1.155  0.00475
1810009O10RIK  ‐1.162  0.00377
MRAS   muscle and microspikes RAS (Mras), mRNA. ‐1.177  0.00219
MTMR11   myotubularin related protein 11 (Mtmr11), mRNA. ‐1.180  0.00424
PHF13   PHD finger protein 13 (Phf13), mRNA. ‐1.189  0.00125
KLC2   kinesin light chain 2 (Klc2), mRNA. ‐1.193  0.00193
MUP3   major urinary protein 3 (Mup3), mRNA. ‐1.204  0.00359
BC039093  ‐1.207  0.0026
AFG3L1   AFG3(ATPase family gene 3)‐like 1 (yeast) (Afg3l1), mRNA. ‐1.208  0.00445
E030027L17  ‐1.209  0.00349
GIMAP7   GTPase, IMAP family member 7 (Gimap7), mRNA. ‐1.213  0.00217
BC030499   cDNA sequence BC030499 (BC030499), mRNA. ‐1.221  0.00219
FBXL6   F‐box and leucine‐rich repeat protein 6 (Fbxl6), mRNA. ‐1.223  0.00333






FCGRT   Fc receptor, IgG, alpha chain transporter (Fcgrt), mRNA. ‐1.254  0.00427
RHBDL1   rhomboid, veinlet‐like 1 (Drosophila) (Rhbdl1), mRNA. ‐1.267  0.00072
CYP2E1   cytochrome P450, family 2, subfamily e, polypeptide 1 (Cyp2e1), mRNA. ‐1.418  0.00107
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